EOM 1352: Fri 7 June 2024, 11:36
Media Pack
News

Current Edition

Volume 18, Issue 1
Discovery Park: Wed 13 November 2024, 10:35
ramusmedical
Regional News

Roche ushers early lung cancer into immunotherapy era with Tecentriq FDA approval. Will doctors follow?

Roche’s Tecentriq has ushered in a new era, offering the first immunotherapy option for non-small cell lung cancer (NSCLC) patients right after tumour surgery. But do...
20 October 2021 Regional News immunotherapy | lung cancer
Continue Reading →
Regional News

In newly diagnosed stomach cancer, 2 Opdivo-Yervoy flops show immunotherapy alone might not be the answer

Bristol Myers Squibb boasts a historic go-ahead for Opdivo plus chemotherapy as the first immunotherapy regimen for previously untreated stomach cancer. But the PD-1 ...
22 September 2021 Regional News Bristol Myers Squibb | immunotherapy
Continue Reading →
Europe

Clinical Trials for CAR T Cells at Bezos Family Immunotherapy Clinic

https://youtu.be/tBH6Y3MQvFs David G. Maloney, MD, PhD, medical director of immunotherapy at the Seattle Cancer Care Alliance and member of Fred Hutchinson Research C...
25 July 2018 Europe | North America Bezos | CAR T
Continue Reading →
Uncategorized

Immunotherapy Clinical Trial Aims for Mesothelioma Cure

Medical oncologist Dr. Bernardo Goulart at the Seattle Cancer Care Alliance (SCCA) believes his latest clinical trial might be the most curative approach to treatment...
25 July 2018 Uncategorized aims | clinical
Continue Reading →
Europe

The University of Texas Md Anderson Cancer Center and Nanobiotix have an agreement to run Immunotherapeutic Pre-Clinical Research in Lung Cancer combining Nbtxr3 and Nivolumab

 NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced th...
11 April 2018 Europe | North America immunotherapy | nanobiotix
Continue Reading →
news

OBI Pharma Announces FDA Clearance Of IND Application For A Phase 1 Study Of A Monoclonal Antibody Cancer Immunotherapy

OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has cleared an investigational new drug ...
24 January 2018 news application | cancer
Continue Reading →
news

Plasticell and Anthony Nolan to partner in clinical trials of ex vivo expanded cord blood stem cells

Plasticell, a developer of innovative stem cell technologies and cell therapies, today announced it will collaborate with Anthony Nolan, a leading research organisati...
5 December 2017 news clinical trial | hematopoietic
Continue Reading →
news

Arcus Biosciences secures funding to advance clinical programs for AB928

Clinical-stage biotechnology company Arcus Biosciences has completed a $107m series C financing, bringing the total equity capital to around $227m. The proceeds from ...
22 November 2017 news biotechnology | cancer
Continue Reading →
Catalyst: 12th January 2026
Quotient

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2026, All Rights Reserved – Powered by Teksyte